QPPV.COM KNOWLEDGE ASSESSMENT

FDA Adverse Event Monitoring System (AEMS): Dashboard Use and Pharmacovigilance Practice

Test your understanding of the concepts covered by FDA Adverse Event Monitoring System (AEMS): Dashboard Use and Pharmacovigilance Practice.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A recent increase in reports follows a public safety communication. What is the most appropriate next step?
Question 2 of 10 A safety reviewer plans to cite an AEMS count in a signal assessment. Which record best supports later review?
Question 3 of 10 A product's AEMS report count rises over several weeks. Which conclusion is best supported by that observation alone?
Question 4 of 10 Which sequence best reflects a defensible use of AEMS in signal management?
Question 5 of 10 A dashboard query shows more reaction entries than distinct cases. What is the most appropriate explanation?
Question 6 of 10 A report is associated with a patient support programme and uses a new E2B(R3) study-type value. What is the primary function of such a value?
Question 7 of 10 Which statement best describes the article's treatment of specified commercial IND safety reports?
Question 8 of 10 A sponsor generalises the 1 October 2026 E2B(R3) date to mean every safety submission to FDA must use ESG NextGen. What is the best correction?
Question 9 of 10 A case lists death as an outcome and a medicine as a suspect product. What is the most defensible interpretation?
Question 10 of 10 A product does not appear on FDA's quarterly potential-signal page. Which conclusion is justified?

Select an answer to continue.

QPPV.com